Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy.

Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study.

Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.

Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor.

Second thoughts about second-look laparotomy in advanced ovarian cancer.

Crossover study with cisplatin or carboplatin in advanced ovarian cancer.

Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer.

Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.

$Intraperitoneal cisplatin in the treatment of refractory or recurrent advanced ovarian carcinoma.$
Intraperitoneal cisplatin in the treatment of refractory or recurrent advanced ovarian carcinoma.

Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin.

A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.

Cyclophosphamide, cisplatin, and abdominal radiation in advanced ovarian cancer.

Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging.

Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer.

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.

Survival after malignant pericardial effusion and cardiac tamponade in advanced ovarian cancer.

A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.

Short-duration (three cycles) cisplatin combination chemotherapy with alkylating agent consolidation in advanced epithelial ovarian cancer.

Intraperitoneal therapy in ovarian cancer: time's up.

Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.

Advanced ovarian cancer: long-term results following chemotherapy and second-look laparotomy.

The integration of whole abdominal radiotherapy and intraperitoneal cisplatin into the primary management of advanced ovarian carcinoma.

Suggest Documents

Intraperitoneal cytosine arabinoside administered in sequence with systemic cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study.

Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.

Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor.

Second thoughts about second-look laparotomy in advanced ovarian cancer.

Crossover study with cisplatin or carboplatin in advanced ovarian cancer.

Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer.

Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.

Intraperitoneal cisplatin in the treatment of refractory or recurrent advanced ovarian carcinoma.

Salvage carboplatin therapy for advanced ovarian cancer after first-line treatment with cisplatin.

A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.

Cyclophosphamide, cisplatin, and abdominal radiation in advanced ovarian cancer.

Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging.

Whole abdomen radiation therapy after a short chemotherapy course and second-look laparotomy in advanced ovarian cancer.

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study.

Survival after malignant pericardial effusion and cardiac tamponade in advanced ovarian cancer.

A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.

Short-duration (three cycles) cisplatin combination chemotherapy with alkylating agent consolidation in advanced epithelial ovarian cancer.

Intraperitoneal therapy in ovarian cancer: time's up.

Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.

Advanced ovarian cancer: long-term results following chemotherapy and second-look laparotomy.

The integration of whole abdominal radiotherapy and intraperitoneal cisplatin into the primary management of advanced ovarian carcinoma.

Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy.

Recommend Documents

Follow Us